Investing Port

P/S	66.52
P/BV	11.58
EV/EBITDA	-104.03
EBITDA	-0.0412
Цена ао	67.84

Все параметры ⇨

		Недооценка Название Значение Оценка P/S 66.52 1 P/BV 11.58 1 P/E 0 EV/EBITDA -104.03 10	Эффективность Название Значение Оценка ROA, % -7 1 ROE, % -17.57 1
	Дивиденды Название Значение Оценка Div yield, % 0 DSI 0 0	Долг Название Значение Оценка Долг/EBITDA 0	Импульс роста Название Значение Оценка Рост прибыли, % 0 0 Рост цены акции, % 0 0 Рост дивидендов, % 0 0

Institutions	Объем	Доля, %
Hartford Funds Management Company, LLC	8153493	11.78
Peroni Portfolio Advisors, Inc	200	0
RA Capital Management, LLC	4826910	6.97
Opaleye Management Inc	356000	0.51
Hennion & Walsh, Inc	100	0
Integral Health Asset Management, LLC	185000	0.27
Cormorant Asset Management, LLC	1400000	2.02
SV Life Sciences Managers LLP	191600	0.28
Wells Fargo Funds Management LLC	381197	0.55
BlackRock Fund Advisors	4454590	6.44
Fidelity SelectCo, LLC	5212989	7.53
Knott David M	75033	0.11
Carmignac Gestion Luxembourg S.A.	58396	0.08
Crow Point Partners, LLC	1990	0
Prudential Retirement Services	123117	0.18
Fidelity Management & Research Company LLC	9783121	14.14
Mangrove Partners	353219	0.51
Northern Trust Investments Inc	942330	1.36
Morningstar	1337621	1.93
Mason Street Advisors, LLC	534954	0.77
Hennion & Walsh, Inc	100	0
Blue Rock Advisors Inc	53784	0.08
Fidelity Management & Research Company LLC	5351027	7.73
Allianz Global Investors GmbH	76692	0.11
Invesco Capital Management LLC	483056	0.7
The Variable Annuity Life Insurance Company	142011	0.21
TimesSquare Capital Management, LLC	25370	0.04

ETF	Доля, %	Доходность за год, %	Дивиденды, %
ALPS Medical Breakthroughs ETF	3.03	34.21	0.50
Invesco DWA Healthcare Momentum ETF	2.68	63.70	0.60
iShares U.S. Pharmaceuticals ETF	1.24	21.89	1.20

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.